Verenigde Staten - Engels - NLM (National Library of Medicine)

amneal pharmaceuticals llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan 6 mg in 1 ml - busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.  busulfan injection is contraindicated in patients with a history of hypersensitivity to any of its components. risk summary busulfan can cause fetal harm when administered to a pregnant woman based on animal data. busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. the solvent, dma, may also cause fetal harm when administered to a pregnant woman. in rats, dma doses of approximately 40% of the daily dose of dma in the busulfan dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies (see data ). there are no available human data informing the drug-associated risk. advise pregnant women of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. animal data following administration during organogenesis in animals, busulfan caused malformations and anomalies, including significant alterations in the musculoskeletal system, body weight gain, and size. in pregnant rats, busulfan produced sterility in both male and female offspring due to the absence of germinal cells in the testes and ovaries. the solvent, n,n-dimethylacetamide (dma), administered to rats at doses of 400 mg/kg/day (about 40% of the daily dose of dma in the busulfan dose on a mg/m2 basis) during organogenesis caused significant developmental anomalies. the most striking abnormalities included anasarca, cleft palate, vertebral anomalies, rib anomalies, and serious anomalies of the vessels of the heart. risk summary it is not known whether busulfan is present in human milk. because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for busulfan in human and animal studies, discontinue breastfeeding during treatment with busulfan. contraception females busulfan can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. advise females of reproductive potential to use effective contraception during treatment with busulfan and for 6 months following cessation of therapy. males busulfan may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. males with female sexual partners of reproductive potential should use effective contraception during treatment with busulfan and for 3 months after cessation of therapy [see nonclinical toxicology (13.1)]. infertility females ovarian suppression and amenorrhea commonly occur in premenopausal women undergoing chronic, low-dose busulfan therapy for chronic myelogenous leukemia. busulfan may cause temporary or permanent infertility in prepubertal girls or in females of child-bearing potential treated with high-dose busulfan in the conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation. males sterility, azoospermia, and testicular atrophy have been reported in male patients. the effectiveness of busulfan in the treatment of cml has not been specifically studied in pediatric patients. an open-label, uncontrolled study evaluated the pharmacokinetics of busulfan in 24 pediatric patients receiving busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic (n=15) or non-malignant diseases (n=9). patients ranged in age from 5 months to 16 years (median 3 years). busulfan dosing was targeted to achieve an area under the plasma concentration curve (auc) of 900 to 1,350 μm•min with an initial dose of 0.8 mg per kg or 1 mg per kg (based on actual body weight (abw)) if the patient was greater than 4 or less than or equal to 4 years, respectively. the dose was adjusted based on plasma concentration after completion of dose 1. patients received busulfan doses every six hours as a two-hour infusion over four days for a total of 16 doses, followed by cyclophosphamide 50 mg per kg once daily for four days. after one rest day, hematopoietic progenitor cells were infused. all patients received phenytoin as seizure prophylaxis. the target auc (900 to 1,350±5% μm•min) for busulfan was achieved at dose 1 in 71% (17/24) of patients. steady-state pharmacokinetic testing was performed at dose 9 and 13. busulfan levels were within the target range for 21 of 23 evaluable patients. all 24 patients experienced neutropenia (absolute neutrophil count (anc) less than 0.5x109 /l) and thrombocytopenia (platelet transfusions or platelet count less than 20,000/mm3 ). seventy-nine percent (19/24) of patients experienced lymphopenia (absolute lymphocyte count less than 0.1x109 ). in 23 patients, the anc recovered to greater than 0.5x109 /l (median time to recovery = bmt day +13; range = bmt day +9 to +22). one patient who died on day +20 had not recovered to an anc >0.5x109 /l. four (17%) patients died during the study. two patients died within 28 days of transplant; one with pneumonia and capillary leak syndrome, and the other with pneumonia and veno-occlusive disease. two patients died prior to day 100; one due to progressive disease and one due to multi-organ failure. adverse reactions were reported in all 24 patients during the study period (bmt day -10 through bmt day +28) or post-study surveillance period (day +29 through +100). these included vomiting (100%), nausea (83%), stomatitis (79%), hvod (21%), graft-versus host disease (gvhd) (25%), and pneumonia (21%). based on the results of this 24-patient clinical trial, a suggested dosing regimen of busulfan in pediatric patients is shown in the following dosing nomogram: busulfan dosing nomogram patient’s actual body weight (abw) busulfan dosage less than or equal to 12 kgs 1.1 (mg per kg) greater than 12 kgs 0.8 (mg per kg) simulations based on a pediatric population pharmacokinetic model indicate that approximately 60% of pediatric patients will achieve a target busulfan exposure (auc) between 900 to 1,350 μm•min with the first dose of busulfan using this dosing nomogram. therapeutic drug monitoring and dose adjustment following the first dose of busulfan is recommended. dose adjustment based on therapeutic drug monitoring instructions for measuring the auc of busulfan at dose 1 (see blood sample collection for auc determination ) and the formula for adjustment of subsequent doses to achieve the desired target auc (1,125 μm•min), are provided below. adjusted dose (mg) = actual dose (mg) x target auc (μm•min)/actual auc (μm•min) for example, if a patient received a dose of 11 mg busulfan and if the corresponding auc measured was 800 μm•min, for a target auc of 1,125 μm•min, the target mg dose would be: mg dose =11 mg x 1,125 μm•min /800 μm•min =15.5 mg busulfan dose adjustment may be made using this formula and instructions below. blood sample collection for auc determination calculate the auc (μm•min) based on blood samples collected at the following time points: for dose 1:2 hr (end of infusion), 4 hr and 6 hr (immediately prior to the next scheduled busulfan administration). actual sampling times should be recorded. for doses other than dose 1: pre-infusion (baseline), 2 hr (end of infusion), 4 hr and 6 hr (immediately prior to the next scheduled busulfan administration). auc calculations based on fewer than the three specified samples may result in inaccurate auc determinations. for each scheduled blood sample, collect one to three ml of blood into heparinized (na or li heparin) vacutainer® tubes. the blood samples should be placed on wet ice immediately after collection and should be centrifuged (at 4°c) within one hour. the plasma, harvested into appropriate cryovial storage tubes, is to be frozen immediately at -20°c. all plasma samples are to be sent in a frozen state (i.e., on dry ice) to the assay laboratory for the determination of plasma busulfan concentrations. calculation of auc busulfan auc calculations may be made using the following instructions and appropriate standard pharmacokinetic formula: dose 1 aucinfinity calculation: aucinfinity = auc0-6hr + aucextrapolated, where auc0-6hr is to be estimated using the linear trapezoidal rule and auc extrapolated can be computed by taking the ratio of the busulfan concentration at hour 6 and the terminal elimination rate constant, λz . the λz must be calculated from the terminal elimination phase of the busulfan concentration vs. time curve. a “0” pre-dose busulfan concentration should be assumed, and used in the calculation of auc. if the auc is assessed subsequent to dose 1, steady-state aucss (auc0-6hr ) is to be estimated from the trough, 2 hr, 4 hr and 6 hr concentrations using the linear trapezoidal rule. instructions for drug administration and blood sample collection for therapeutic drug monitoring use an administration set with minimal residual hold up (priming) volume (1 ml to 3 ml) for drug infusion to ensure accurate delivery of the entire prescribed dose and to ensure accurate collection of blood samples for therapeutic drug monitoring and dose adjustment. prime the administration set tubing with drug solution to allow accurate documentation of the start time of busulfan infusion. collect the blood sample from a peripheral iv line to avoid contamination with infusing drug. if the blood sample is taken directly from the existing central venous catheter (cvc), do not collect the blood sample while the drug is infusing to ensure that the end of infusion sample is not contaminated with any residual drug. at the end of infusion (2 hr), disconnect the administration tubing and flush the cvc line with 5 ml of normal saline prior to the collection of the end of infusion sample from the cvc port. collect the blood samples from a different port than that used for the busulfan infusion. when recording the busulfan infusion stop time, do not include the time required to flush the indwelling catheter line. discard the administration tubing at the end of the two-hour infusion [see dosage and administration (2.3)]. clinical studies of busulfan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Verenigde Staten - Engels - NLM (National Library of Medicine)

mutual pharmaceutical company - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate (unii: h527kap6l5) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - tablet - 1.25 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful

Verenigde Staten - Engels - NLM (National Library of Medicine)

northwind pharmaceuticals - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis media f

Verenigde Staten - Engels - NLM (National Library of Medicine)

teva parenteral medicines, inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 80 mg in 1 ml - sulfamethoxazole and trimethoprim injection is indicated in the treatment of pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris when oral administration of sulfamethoxazole and trimethoprim injection is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract. to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxa

Verenigde Staten - Engels - NLM (National Library of Medicine)

mylan institutional llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 80 mg in 1 ml - sulfamethoxazole and trimethoprim injection is indicated in the treatment of pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris when oral administration of sulfamethoxazole and trimethoprim injection is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract. to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethox

Verenigde Staten - Engels - NLM (National Library of Medicine)

greenstone llc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets are indicated: sulfasalazine tablets are contraindicated in: none reported.

Verenigde Staten - Engels - NLM (National Library of Medicine)

par pharmaceutical - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets, usp are indicated: - in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and - for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: -  patients with intestinal or urinary obstruction, -  patients with porphyria as sulfonamides have been reported to precipitate an acute attack, -  patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.

Verenigde Staten - Engels - NLM (National Library of Medicine)

greenstone llc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine delayed release tablets are indicated: sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent. sulfasalazine delayed release tablets are con

Verenigde Staten - Engels - NLM (National Library of Medicine)

actavis pharma, inc. - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and b) for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: patients with intestinal or urinary obstruction, patients with porphyria as sulfonamides have been reported to precipitate an acute attack, patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.

Verenigde Staten - Engels - NLM (National Library of Medicine)

blenheim pharmacal, inc. - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets, usp are indicated: - in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and - for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: -  patients with intestinal or urinary obstruction, -  patients with porphyria as sulfonamides have been reported to precipitate an acute attack, -  patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.